Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


28.01.2019

1 Am J Clin Oncol
2 Ann Surg Oncol
5 BMC Cancer
1 Cancer Lett
3 Clin Cancer Res
2 Clin Lung Cancer
1 Clin Nucl Med
2 Eur J Cancer
2 Int J Cancer
2 Int J Oncol
2 Int J Radiat Oncol Biol Phys
2 J Clin Oncol
1 J Comput Assist Tomogr
1 J Thorac Cardiovasc Surg
6 J Thorac Oncol
1 Mol Carcinog
1 Nat Med
1 Oncol Rep
1 Oncologist
3 PLoS One
2 Proc Natl Acad Sci U S A
1 Thorax


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Oncol

  1. SU CT, Chau V, Halmos B, Shah CD, et al
    Impact of Primary Care Access on Mortality of Lung Cancer Patients in an Underserved Community.
    Am J Clin Oncol. 2019 Jan 16. doi: 10.1097/COC.0000000000000516.
    PubMed     Text format     Abstract available


    Ann Surg Oncol

  2. YAMAGUCHI S, Morita M, Yamamoto M, Egashira A, et al
    Long-Term Outcome of Definitive Chemoradiotherapy and Induction Chemoradiotherapy Followed by Surgery for T4 Esophageal Cancer with Tracheobronchial Invasion.
    Ann Surg Oncol. 2018;25:3280-3287.
    PubMed     Text format     Abstract available

  3. MALGRAS B, Gayat E, Aoun O, Lo Dico R, et al
    Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.
    Ann Surg Oncol. 2018;25:3271-3279.
    PubMed     Text format     Abstract available


    BMC Cancer

  4. YIN X, Yan D, Qiu M, Huang L, et al
    Prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:95.
    PubMed     Text format     Abstract available

  5. CEA SORIANO L, Zong J, Garcia Rodriguez LA
    Feasibility and validity of The Health Improvement Network database of primary care electronic health records to identify and characterise patients with small cell lung cancer in the United Kingdom.
    BMC Cancer. 2019;19:91.
    PubMed     Text format     Abstract available

  6. XU J, Guo W, Xie L
    Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
    BMC Cancer. 2018;18:987.
    PubMed     Text format     Abstract available

  7. KIM MK, Yee J, Cho YS, Jang HW, et al
    Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study.
    BMC Cancer. 2018;18:988.
    PubMed     Text format     Abstract available

  8. SABATH B, Muhammad HA, Balagani A, Ost DE, et al
    Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study.
    BMC Cancer. 2018;18:937.
    PubMed     Text format     Abstract available


    Cancer Lett

  9. HUANG H, Wang Y, Li Q, Fei X, et al
    miR-140-3p functions as a tumor suppressor in squamous cell lung cancer by regulating BRD9.
    Cancer Lett. 2019 Jan 17. pii: S0304-3835(19)30019.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  10. PLANCHARD D, Boyer MJ, Lee JS, Dechaphunkul A, et al
    Post-Progression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2019 Jan 18. pii: 1078-0432.CCR-18-3325.
    PubMed     Text format     Abstract available

  11. BALTSCHUKAT S, Schacher Engstler B, Huang A, Hao HX, et al
    Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
    Clin Cancer Res. 2019 Jan 23. pii: 1078-0432.CCR-18-2814.
    PubMed     Text format     Abstract available

  12. YUN J, Hong MH, Kim SY, Park CW, et al
    YH25448, an irreversible EGFR-TKI with Potent Intracranial Activity in EGFR mutant non-small-cell lung cancer.
    Clin Cancer Res. 2019 Jan 22. pii: 1078-0432.CCR-18-2906.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  13. WANG L, Zhan C, Gu J, Xi J, et al
    Role of Skip Mediastinal Lymph Node Metastasis for Patients With Resectable Non-small-cell Lung Cancer: A Propensity Score Matching Analysis.
    Clin Lung Cancer. 2018 Dec 19. pii: S1525-7304(18)30331.
    PubMed     Text format     Abstract available

  14. DALWADI SM, Lewis GD, Bernicker EH, Butler EB, et al
    Disparities in the Treatment and Outcome of Stage I Non-Small-Cell Lung Cancer in the 21st Century.
    Clin Lung Cancer. 2018 Nov 20. pii: S1525-7304(18)30300.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  15. EDEL JP, Balink H
    18F-FDG PET/CT Revealing Constrictive Pericarditis as the Only Manifestation of Malignant Mesothelioma.
    Clin Nucl Med. 2018 Oct 27. doi: 10.1097/RLU.0000000000002349.
    PubMed     Text format     Abstract available


    Eur J Cancer

  16. LEVY BP, Giaccone G, Besse B, Felip E, et al
    Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
    Eur J Cancer. 2019;108:120-128.
    PubMed     Text format     Abstract available

  17. BASAK EA, Koolen SLW, Hurkmans DP, Schreurs MWJ, et al
    Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer.
    Eur J Cancer. 2019;109:12-20.
    PubMed     Text format     Abstract available


    Int J Cancer

  18. LIU Y, Yang Q, Yang J, Cao R, et al
    Characteristics and prognostic significance of profiling the peripheral blood T-cell receptor repertoire in patients with advanced lung cancer.
    Int J Cancer. 2019 Jan 21. doi: 10.1002/ijc.32145.
    PubMed     Text format     Abstract available

  19. YANG L, Dong Y, Li Y, Wang D, et al
    IL-10 derived from M2 macrophage promotes cancer stemness via JAK1/STAT1/NF-kappaB/Notch1 pathway in non-small cell lung cancer.
    Int J Cancer. 2019 Jan 22. doi: 10.1002/ijc.32151.
    PubMed     Text format     Abstract available


    Int J Oncol

  20. XU YH, Tu JR, Zhao TT, Xie SG, et al
    [Corrigendum] Overexpression of lncRNA EGFRAS1 is associated with a poor prognosis and promotes chemotherapy resistance in nonsmall cell lung cancer.
    Int J Oncol. 2019 Jan 14. doi: 10.3892/ijo.2019.4686.
    PubMed     Text format     Abstract available

  21. WANG Z, Liu G, Jiang J
    Profiling of apoptosis- and autophagy-associated molecules in human lung cancer A549 cells in response to cisplatin treatment using stable isotope labeling with amino acids in cell culture.
    Int J Oncol. 2019 Jan 18. doi: 10.3892/ijo.2019.4690.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  22. BERLIN E, Buckstein M, Yip R, Yankelevitz DF, et al
    Definitive Radiation for Stage I lung cancer in a screened population: Results from the I-ELCAP.
    Int J Radiat Oncol Biol Phys. 2019 Jan 21. pii: S0360-3016(19)30110.
    PubMed     Text format     Abstract available

  23. MARQUEZ C
    Observe, and Keep Chemotherapy Up the Sleeve.
    Int J Radiat Oncol Biol Phys. 2018;100:550.
    PubMed     Text format    


    J Clin Oncol

  24. LAI GGY, Lim TH, Lim J, Liew PJR, et al
    Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Jan 24:JCO1800177. doi: 10.1200/JCO.18.00177.
    PubMed     Text format     Abstract available

  25. LISBERG A, Garon EB
    Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?
    J Clin Oncol. 2019 Jan 24:JCO1801534. doi: 10.1200/JCO.18.01534.
    PubMed     Text format    


    J Comput Assist Tomogr

  26. E L, Lu L, Li L, Yang H, et al
    Radiomics for Classifying Histological Subtypes of Lung Cancer Based on Multiphasic Contrast-Enhanced Computed Tomography.
    J Comput Assist Tomogr. 2019 Jan 17. doi: 10.1097/RCT.0000000000000836.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  27. FERRARI-LIGHT D, Cerfolio RJ
    Are we really operating on advanced stage non-small cell lung cancer?
    J Thorac Cardiovasc Surg. 2018 Dec 4. pii: S0022-5223(18)33219.
    PubMed     Text format    


    J Thorac Oncol

  28. WU YL, Lu S, Cheng Y, Zhou C, et al
    Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer: CheckMate 078 Randomized Phase III Clinical Trial.
    J Thorac Oncol. 2019 Jan 16. pii: S1556-0864(19)30020.
    PubMed     Text format     Abstract available

  29. PUJOL JL, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al
    A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT-1603 Trial.
    J Thorac Oncol. 2019 Jan 18. pii: S1556-0864(19)30025.
    PubMed     Text format     Abstract available

  30. DAGOGO-JACK I, Rooney M, Nagy RJ, Lin JJ, et al
    Molecular Analysis of Plasma from Patients with ROS1-Positive Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Jan 18. pii: S1556-0864(19)30027.
    PubMed     Text format     Abstract available

  31. TSENG CH, Tsuang BJ, Chiang CJ, Ku KC, et al
    The relationship between air pollution and lung cancer in non-smokers in Taiwan.
    J Thorac Oncol. 2019 Jan 18. pii: S1556-0864(19)30026.
    PubMed     Text format     Abstract available

  32. RECK M, Horn L, Novello S, Barlesi F, et al
    Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small-Cell Lung Cancer.
    J Thorac Oncol. 2019 Jan 21. pii: S1556-0864(19)30029.
    PubMed     Text format     Abstract available

  33. DAGOGO-JACK I, Robinson H, Mino-Kenudson M, Farago AF, et al
    Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients with Minimal Smoking History.
    J Thorac Oncol. 2019 Jan 17. pii: S1556-0864(19)30024.
    PubMed     Text format     Abstract available


    Mol Carcinog

  34. WANG S, Cheng Y, Gao Y, He Z, et al
    SH2B1 promotes epithelial-mesenchymal transition through the IRS1/beta-catenin signaling axis in lung adenocarcinoma.
    Mol Carcinog. 2018;57:640-652.
    PubMed     Text format     Abstract available


    Nat Med

  35. TEIXEIRA VH, Pipinikas CP, Pennycuick A, Lee-Six H, et al
    Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions.
    Nat Med. 2019 Jan 21. pii: 10.1038/s41591-018-0323.
    PubMed     Text format     Abstract available


    Oncol Rep

  36. MUN JG, Kee JY, Han YH, Lee S, et al
    Galla Rhois water extract inhibits lung metastasis by inducing AMPKmediated apoptosis and suppressing metastatic properties of colorectal cancer cells.
    Oncol Rep. 2018 Oct 22. doi: 10.3892/or.2018.6812.
    PubMed     Text format     Abstract available


    Oncologist

  37. NAKAO A, Hiranuma O, Uchino J, Sakaguchi C, et al
    Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial.
    Oncologist. 2019 Jan 16. pii: theoncologist.2019-0003.
    PubMed     Text format     Abstract available


    PLoS One

  38. NISHIO M, Kubo T, Togashi K
    Estimation of lung cancer risk using homology-based emphysema quantification in patients with lung nodules.
    PLoS One. 2019;14:e0210720.
    PubMed     Text format     Abstract available

  39. AGEMI Y, Shimokawa T, Sasaki J, Miyazaki K, et al
    Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: A single-institution study.
    PLoS One. 2019;14:e0210499.
    PubMed     Text format     Abstract available

  40. MESALLES-NARANJO O, Grant I, Wyper GMA, Stockton D, et al
    Trends and inequalities in the burden of mortality in Scotland 2000-2015.
    PLoS One. 2018;13:e0196906.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  41. AMELIO I, Mancini M, Petrova V, Cairns RA, et al
    p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression.
    Proc Natl Acad Sci U S A. 2018;115:E10869-E10878.
    PubMed     Text format     Abstract available

  42. SCHALLY AV, Wang H, He J, Cai R, et al
    Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH.
    Proc Natl Acad Sci U S A. 2018;115:12028-12033.
    PubMed     Text format     Abstract available


    Thorax

  43. ADIZIE JB, Khakwani A, Beckett P, Hubbard R, et al
    Impact of organisation and specialist service delivery on lung cancer outcomes.
    Thorax. 2019 Jan 19. pii: thoraxjnl-2018-212588.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: